Empagliflozin/linagliptin/metformin
Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a drug combination used for the treatment of type 2 diabetes. It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.
| Combination of | |
|---|---|
| Empagliflozin | SGLT2 inhibitor |
| Linagliptin | DPP-4 inhibitor |
| Metformin | Anti-diabetic biguanide |
| Clinical data | |
| Trade names | Trijardy XR |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.